PSMA1-Mediated Ultrasmall Gold Nanoparticles Facilitate Tumor Targeting and MR/CT/NIRF Multimodal Detection of Early-Stage Prostate Cancer

Investigators devised a multimodal contrast agent that featured highly-effective PSMA targeting and desired molecular pharmacokinetics for prostate cancer diagnosis.